Niloufar Mohammadkhani

732 total citations · 2 hit papers
11 papers, 467 citations indexed

About

Niloufar Mohammadkhani is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Niloufar Mohammadkhani has authored 11 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Immunology. Recurrent topics in Niloufar Mohammadkhani's work include CAR-T cell therapy research (2 papers), Immunotherapy and Immune Responses (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Niloufar Mohammadkhani is often cited by papers focused on CAR-T cell therapy research (2 papers), Immunotherapy and Immune Responses (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Niloufar Mohammadkhani collaborates with scholars based in Iran, Germany and Canada. Niloufar Mohammadkhani's co-authors include Mehdi Shakibaei, Anna‐Lena Mueller, Zahra Payandeh, Aranka Brockmueller, Alireza Zakeri, Armina Alagheband Bahrami, Huda Fatima Rajani, Saeedeh Nouri-Majd, Francisco Veiga and Ana Cláudia Paiva‐Santos and has published in prestigious journals such as Molecules, Life Sciences and European Journal of Pharmacology.

In The Last Decade

Niloufar Mohammadkhani

11 papers receiving 463 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Naringenin: A potential flavonoid phytochemical for cancer therapy

2022 179 citations Mahzad Motallebi, Mohammed Bhia et al. Life Sciences profile →
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies

2021 152 citations Anna‐Lena Mueller, Zahra Payandeh et al. Cells profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Niloufar Mohammadkhani Iran	9	190	100	89	85	66	11	467
Anna‐Lena Mueller Germany	10	234 1.2×	61 0.6×	56 0.6×	124 1.5×	63 1.0×	15	579
Prashasnika Gehlot United States	7	189 1.0×	144 1.4×	72 0.8×	38 0.4×	85 1.3×	10	538
Yonghui Dong China	12	335 1.8×	134 1.3×	40 0.4×	62 0.7×	60 0.9×	21	577
Jiyoung Lee South Korea	10	140 0.7×	35 0.3×	58 0.7×	67 0.8×	48 0.7×	24	696
Mojtaba Abbasi Iran	14	270 1.4×	94 0.9×	95 1.1×	169 2.0×	86 1.3×	27	755
Abby VanVoorhees United States	7	146 0.8×	83 0.8×	159 1.8×	65 0.8×	67 1.0×	9	510
Lixia Bai China	13	279 1.5×	100 1.0×	67 0.8×	30 0.4×	71 1.1×	28	538
Yuzhou Pang China	12	148 0.8×	50 0.5×	46 0.5×	102 1.2×	64 1.0×	24	411
Mengyao Sun China	15	414 2.2×	97 1.0×	76 0.9×	57 0.7×	125 1.9×	36	725
Xiong Li China	13	254 1.3×	150 1.5×	156 1.8×	188 2.2×	43 0.7×	38	849

Countries citing papers authored by Niloufar Mohammadkhani

Since Specialization

Citations

This map shows the geographic impact of Niloufar Mohammadkhani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niloufar Mohammadkhani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niloufar Mohammadkhani more than expected).

Fields of papers citing papers by Niloufar Mohammadkhani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niloufar Mohammadkhani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niloufar Mohammadkhani. The network helps show where Niloufar Mohammadkhani may publish in the future.

Co-authorship network of co-authors of Niloufar Mohammadkhani

This figure shows the co-authorship network connecting the top 25 collaborators of Niloufar Mohammadkhani. A scholar is included among the top collaborators of Niloufar Mohammadkhani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niloufar Mohammadkhani. Niloufar Mohammadkhani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Mohammadkhani, Niloufar, et al.. (2023). Update on immune‐based therapy strategies targeting cancer stem cells. Cancer Medicine. 12(18). 18960–18980. 14 indexed citations

2.

Far, Bahareh Farasati, et al.. (2023). Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. Medical Oncology. 40(8). 243–243. 19 indexed citations

3.

Rajabi, Sadegh, Huda Fatima Rajani, Niloufar Mohammadkhani, et al.. (2023). Long Non-Coding RNAs as Novel Targets for Phytochemicals to Cease Cancer Metastasis. Molecules. 28(3). 987–987. 6 indexed citations

4.

Motallebi, Mahzad, Mohammed Bhia, Huda Fatima Rajani, et al.. (2022). Naringenin: A potential flavonoid phytochemical for cancer therapy. Life Sciences. 305. 120752–120752. 179 indexed citations breakdown →

5.

Fath, Mohsen Karami, Ali Azargoonjahromi, Niloufar Mohammadkhani, et al.. (2022). Exosome application in tumorigenesis: diagnosis and treatment of melanoma. Medical Oncology. 39(2). 19–19. 12 indexed citations

6.

Taleb, Mohammad, et al.. (2022). Modulation of Tumor Vasculature Network: Key Strategies. Small Structures. 3(6). 10 indexed citations

7.

Mueller, Anna‐Lena, Zahra Payandeh, Niloufar Mohammadkhani, et al.. (2021). Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. Cells. 10(11). 3017–3017. 152 indexed citations breakdown →

8.

Poorebrahim, Mansour, et al.. (2021). Correction: TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential. Cancer Gene Therapy. 28(6). 738–738. 1 indexed citations

9.

Poorebrahim, Mansour, et al.. (2021). TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential. Cancer Gene Therapy. 28(6). 581–589. 40 indexed citations

10.

Payandeh, Zahra, Niloufar Mohammadkhani, Mohsen Nabi‐Afjadi, et al.. (2020). The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. Expert Review of Anti-infective Therapy. 19(7). 899–910. 10 indexed citations

11.

Mohammadkhani, Niloufar, et al.. (2019). Statins: Complex outcomes but increasingly helpful treatment options for patients. European Journal of Pharmacology. 863. 172704–172704. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact